Kymera Therapeutics (KYMR) Return on Capital Employed (2020 - 2026)
Kymera Therapeutics' (KYMR) quarterly Return on Capital Employed came in at 21.85% in Q1 2026, up 944.0% year-on-year from 2.09% in Q1 2025, and up 16.23% on a QoQ basis from 26.09% in Q4 2025.
Kymera Therapeutics (KYMR) Return on Capital Employed (2020 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 7 years of Return on Capital Employed data on file, last reported at 21.85% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 944.0% year-over-year to 21.85% in Q1 2026; TTM through Mar 2026 was 21.85%, a 944.0% increase from a year earlier, with the FY2025 full-year figure at 27.36%, up 954.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 21.85%, up from 26.09% in the prior quarter.
- Over the last five years, Return on Capital Employed for KYMR reached as high as 21.85% in Q1 2026 and fell as low as 36.68% in Q3 2023.
- Historically, Return on Capital Employed has averaged 29.23% across 5 years, with a median of 30.8% in 2022.
- Across the five-year window, Return on Capital Employed tumbled 1411 bps in 2022 and jumped 1350 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 29.35% in 2022, then declined by 18 bps to 34.6% in 2023, then grew by 19 bps to 27.87% in 2024, then climbed by 6 bps to 26.09% in 2025, then rose by 16 bps to 21.85% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 21.85% in Q1 2026, 26.09% in Q4 2025, and 31.8% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Kymera Therapeutics | 10.77 Bn | 10.11 Bn | - | -21.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.85% |
| Dec 31, 2025 | -26.09% |
| Sep 30, 2025 | -31.80% |
| Jun 30, 2025 | -33.28% |
| Mar 31, 2025 | -31.29% |
| Dec 31, 2024 | -27.87% |
| Sep 30, 2024 | -23.17% |
| Jun 30, 2024 | -23.64% |
| Mar 31, 2024 | -26.74% |
| Dec 31, 2023 | -34.60% |
| Sep 30, 2023 | -36.68% |
| Jun 30, 2023 | -31.70% |
| Mar 31, 2023 | -31.04% |
| Dec 31, 2022 | -29.35% |
| Sep 30, 2022 | -31.97% |
| Jun 30, 2022 | -30.80% |
| Mar 31, 2022 | -25.05% |
| Dec 31, 2021 | -18.91% |
| Sep 30, 2021 | -17.87% |
| Jun 30, 2021 | -17.24% |